Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis

References

• HeinemannVvon WeikersthalLFDeckerTFOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialLancet Oncol201415101065107525088940
   PubMed Web of Science ®Google Scholar
• RiveraFKarthausMHechtJRFinal analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinomaInt J Colorectal Dis20173281179119028424871
   PubMed Web of Science ®Google Scholar
• VenookAPNiedzwieckiDLenzHJEffect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trialJAMA2017317232392240128632865
   PubMed Web of Science ®Google Scholar
• KhattakMAMartinHDavidsonAPhillipsMRole of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trialsClin Colorectal Cancer2015142819025666296
   PubMed Web of Science ®Google Scholar
• PietrantonioFCremoliniCPetrelliFFirst-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysisCrit Rev Oncol Hematol201596115616626088456
   PubMed Web of Science ®Google Scholar
• TamburiniERudnasBGianniLE02*Anti-EGFR or bevaci-zumab in first line treatment of RAS wild type metastatic colorectal neoplasm (RwtMCRC): meta-analysis of randomized clincal trialsAnn Oncol201526Suppl 6vi36
   Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
   PubMed Web of Science ®Google Scholar
• SclafaniFCunninghamDCetuximab or bevacizumab in metastatic colorectal cancer?Lancet Oncol201415101040104125088941
   PubMed Web of Science ®Google Scholar
• ModestDPStintzingSvon WeikersthalLFImpact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancerJ Clin Oncol201533323718372626261259
   PubMed Web of Science ®Google Scholar
• ModestDPStintzingSvon WeikersthalLFExploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)Oncotarget201786210574910576029285289
   PubMedGoogle Scholar
• VenookAPNiedzwieckiDInnocentiFImpact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance)J Clin Oncol201634350415_suppl3504
   Google Scholar
• Pàez-RibesMAllenEHudockJAntiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasisCancer Cell200915322023119249680
   PubMed Web of Science ®Google Scholar
• ZhouLLiuXDSunMTargeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinomaOncogene201635212687269726364599
   PubMed Web of Science ®Google Scholar
• WainbergZADrakakiAThe importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitorsExpert Opin Biol Ther20151581205122026066903
   PubMed Web of Science ®Google Scholar
• DerangèreVFumetJDBoidotRDoes bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?Oncotarget2016789309932126824184
   PubMedGoogle Scholar
• MoehlerMThomaidisTZeifriCInclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?J Cancer Res Clin Oncol2015141351552225230900
   PubMed Web of Science ®Google Scholar
• SatoYMatsusakaSSuenagaMShinozakiEMizunumaNCetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patientsOnco Targets Ther201583329333626648737
   PubMed Web of Science ®Google Scholar
• NorguetEDahanLGaudartJGasmiMOuafikLSeitzJFCetux-imab after bevacizumab in metastatic colorectal cancer: is it the best sequence?Dig Liver Dis2011431191791921763224
   PubMedGoogle Scholar
• HasegawaHTaniguchiHMitaniSEfficacy of second-line bevacizumab-containing chemotherapy for patients with metastatic colorectal cancer following first-line treatment with an anti-epidermal growth factor receptor antibodyOncology201792420521228142137
   PubMed Web of Science ®Google Scholar
• TaniguchiHKomoriANaritaYA short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancerJpn J Clin Oncol201646322823326759349
   PubMed Web of Science ®Google Scholar
• PriceTKimTWLiJFinal results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancerEur J Cancer201668515927716478
   PubMed Web of Science ®Google Scholar
• HiretSBorgCBertautABevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtKRAS metastatic colorectal cancer: a random-ized phase II study (Prodige 18 –UNICANCER GI)J Clin Oncol20163415_suppl35143514
   Google Scholar
• PriceTJHardinghamJKarapetisC524P Bevacizumab first line and impact on subsequent anti-EGFR activityAnn Oncol201728050suppl_5mdx393.050
   Google Scholar
• BennounaJSastreJArnoldDML18147 Study InvestigatorsContinuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trialLancet Oncol2013141293723168366
   PubMed Web of Science ®Google Scholar
• ChibaudelBBonnetainFTournigandCSTRATEGIC-1: a multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancerBMC Cancer201515149626141683
   PubMedGoogle Scholar
• von EinemJCHeinemannVvon WeikersthalLFLeft-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trialJ Cancer Res Clin Oncol201414091607161424816724
   PubMed Web of Science ®Google Scholar
• LoupakisFYangDYauLPrimary tumor location as a prognostic factor in metastatic colorectal cancerJ Natl Cancer Inst201531073dju42725713148
   PubMedGoogle Scholar
• TejparSStintzingSCiardielloFPrognostic and predictive relevance of primary tumor location in patients with ras wild-type metastatic colorectal cancer retrospective analyses of the CRYSTAL and FIRE-3 trialsJAMA Oncol201636014
   Google Scholar
• WangFBaiLLiuTSRight-sided colon cancer and left-sided colorectal cancers respond differently to cetuximabChin J Cancer201534938439326111811
   PubMedGoogle Scholar
• BruléSYJonkerDJKarapetisCSLocation of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17Eur J Cancer201551111405141425979833
   PubMed Web of Science ®Google Scholar
• ChenKHShaoYYChenHMPrimary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort studyBMC Cancer20161632727221731
   PubMed Web of Science ®Google Scholar
• MorettoRCremoliniCRossiniDLocation of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and braf wild-type metastatic colorectal cancerOncologist201621898899427382031
   PubMed Web of Science ®Google Scholar
• HolchJWRicardIStintzingSModestDPHeinemannVThe relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trialsEur J Cancer201770879827907852
   PubMed Web of Science ®Google Scholar
• De RoockWClaesBBernasconiDEffects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisLancet Oncol201011875376220619739
   PubMed Web of Science ®Google Scholar
• DouillardJYOlinerKSSienaSPanitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancerN Engl J Med2013369111023103424024839
   PubMed Web of Science ®Google Scholar
• Van CutsemELenzHJKöhneCHFluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancerJ Clin Oncol201533769270025605843
   PubMed Web of Science ®Google Scholar
• van HeldenEJMenke-van der Houven van OordtCWHeymansMWKetJCFvan den OordRVerheulHMWOptimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysisCancer Metastasis Rev201736239540628695301
   PubMed Web of Science ®Google Scholar
• PeetersMPriceTJCervantesARandomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancerJ Clin Oncol201028314706471320921462
   PubMed Web of Science ®Google Scholar
• CorrealePMarraMRemondoCCytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC)Eur J Cancer20104691703171120399639
   PubMed Web of Science ®Google Scholar
• FialaOVeskrnovaVChloupkovaRImpact of delayed addition of anti-EGFR monoclonal antibodies on the outcome of first-line therapy in metastatic colorectal cancer patients: a retrospective registry-based analysisTarget Oncol201813673574330353488
   PubMed Web of Science ®Google Scholar